Replies to post #586 on PROTALIX BIOTHERAPEUTICS, INC. (PLX)

[robbie1165]

I guess we can look on the bright side and call it an extended free trial period.
BTW: PLX did get an upgrade from CapStone today from buy to strong buy.
July 12, 2010 3:47 PM EDT

CapStone has issued an intraday upgrade on shares of Protalix BioTherapeutics (AMEX: PLX) today following news that the company's NDA for taliglucerase alfa has been accepted for review by the FDA. The stock is down 4.4% to $6.04 today.

The firm now rates Protalix shares a Strong Buy, up from Buy previously, and also raised the stock's price target from $8.50 to $10. CapStone calls the news "positive as it eliminates one uncertainity from getting the NDA approval."

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system primarily in the United States.

http://www.streetinsider.com/Upgrades/CapStone+Upgrades+Protalix+(PLX)+to+Strong+Buy%3B+Calls+Taliglucerase+Alfa+News+a+Positive/5798487.html